Patents Assigned to Deciphera Pharmaceuticals LLC
  • Patent number: 12213967
    Abstract: Provided herein are low impurity compositions comprising a compound represented which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: August 6, 2024
    Date of Patent: February 4, 2025
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 12213968
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: August 6, 2024
    Date of Patent: February 4, 2025
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 12102620
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: October 1, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • Patent number: 12071432
    Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
    Type: Grant
    Filed: June 6, 2022
    Date of Patent: August 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Yu Mi Ahn, Timothy Caldwell, Lakshminarayana Vogeti
  • Patent number: 12064422
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: August 20, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 12059411
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: August 13, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 12059410
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: August 13, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 12023327
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: July 2, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 12023325
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: July 2, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 12023328
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: July 2, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 12023326
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: July 2, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 11986463
    Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: May 21, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Anu Gupta
  • Patent number: 11969415
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: November 22, 2023
    Date of Patent: April 30, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 11969414
    Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: April 30, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
  • Patent number: 11918564
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: March 5, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 11911370
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: February 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 11912668
    Abstract: Described herein are compounds, such as compounds represented by Formula I-R: and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
  • Patent number: 11903933
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: February 20, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Patent number: 11896585
    Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: February 13, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
  • Publication number: 20230414614
    Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
    Type: Application
    Filed: April 28, 2023
    Publication date: December 28, 2023
    Applicant: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida